Safety and efficacy of S-1 chemotherapy in recurrent/metastatic head and neck cancer

Suzuki, Shinsuke; Ishikawa, Kazuo

doi:10.1007/s10156-009-0712-x

Cited by 8 publications

(2 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients received weekly paclitaxel at a dose of 80 mg/m 2 , followed by weekly cetuximab at a dose of 400 mg/m 2 on the first day and 250 mg/m 2 on the other days. S1 is an orally active combination of tegafur (a prodrug that is converted by cells to fluorouracil), gimeracil (an inhibitor of dihydropyrimidine dehydrogenase, which degrades fluorouracil), and oteracil (an inhibitor of the phosphorylation of fluorouracil in the gastrointestinal tract, which thereby reduces the gastrointestinal toxic effects of fluorouracil) [ 24 , 25 , 26 , 27 ]. S1 was administered at a dose of 80–120 mg/body/day according to the body surface area in accordance with the drug information.…”

Section: Methodsmentioning

confidence: 99%

Prognostic Biomarkers of Salvage Chemotherapy Following Nivolumab Treatment for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma

Wakasaki

Yasumatsu

Masuda

et al. 2020

Cancers

View full text Add to dashboard Cite

Recent studies have suggested the benefit of salvage chemotherapy (SCT) after immune checkpoint inhibitor (ICI) treatment for recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC). We retrospectively examined the outcome of SCT and the usefulness of the serum C-reactive protein level (CRP) and neutrophil-to-lymphocyte ratio (NLR) as prognostic biomarkers. Thirty-nine patients with R/M HNSCC were enrolled in this study. Twenty-five patients (64.1%) received combination chemotherapy of weekly paclitaxel and cetuximab (PC) as SCT, and 14 patients (35.9%) received tegafur-gimestat-otastat potassium (S1), an oral fluoropyrimidine. In all patients, the response rate, disease control rate, median progression-free survival (PFS), and median overall survival (OS) were 45.2%, 85.7%, 6.5 months, and 13.5 months, respectively. No chemotherapy-related deaths were observed. These PC groups had low CRP (<1.2 mg/dL) or low NLR (<7.0) values at the time of SCT induction, which was significantly associated with an improved OS (p = 0.0440, p = 0.0354). A multivariate analysis also showed that a lower CRP value was significantly associated with a better OS (p = 0.0078). We clarified the usefulness of the PC and S1 regimens as SCT. In addition, SCT with the PC regimen showed a better prognosis with a lower CRP or NLR at induction than a higher CRP or NLR. This is the first report on biomarkers of SCT in R/M HNSCC.

show abstract

Section: Methodsmentioning

confidence: 99%

Prognostic Biomarkers of Salvage Chemotherapy Following Nivolumab Treatment for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma

Wakasaki

Yasumatsu

Masuda

et al. 2020

Cancers

View full text Add to dashboard Cite

show abstract

“…Nedaplatin has been reported to be at least as effective as cisplatin for HNSCC (18,19). In S-1, tegafur is a prodrug of 5-fluorouracil, 5-chloro-2,4-dehydroxypyrimidine enhances the serum 5-fluorouracil concentrations, and potassium oxonate reduces adverse reactions in the digestive tract (20). Five patients with T2 laryngeal cancer and one with decreased renal function received weekly docetaxel (10 mg/m 2 ) chemotherapy 4-6 times concomitantly with RT.…”

Section: Treatment and Follow-upmentioning

confidence: 99%

Usefulness of 3′-Deoxy-3′-¹⁸F-Fluorothymidine PET for Predicting Early Response to Chemoradiotherapy in Head and Neck Cancer

et al. 2012

View full text Add to dashboard Cite

This study compared the utility of 39-deoxy-39-18 F-fluorothymidine PET ( 18 F-FLT PET) with that of 18 F-FDG PET for assessment of the early locoregional clinical outcomes of chemoradiotherapy for head and neck squamous cell carcinomas. Methods: From May 2006 to September 2010, 28 patients with head and neck squamous cell carcinomas underwent 18 F-FLT and 18 F-FDG PET before radiation therapy (RT), 4 wk after the initiation of RT, and 5 wk after completion of RT. PET images were evaluated qualitatively for regions of focally increased metabolism and were analyzed in relation to residual accumulation and local disease control. Results: During RT, 18 F-FLT uptake decreased more significantly than 18 F-FDG uptake. 18 F-FLT accumulations disappeared in 34 of 54 lesions (63%), and negative predictive value was 97%. 18 F-FDG PET during RT also had a high negative predictive value (100%), but only 9 lesions (16%) showed complete absence of accumulation. The specificity and overall accuracy of 18 F-FLT PET were significantly higher than those of 18 F-FDG PET both during and after RT. In particular, high significance was attributable to the results of the evaluations of primary lesions. There were significant differences in 3-y local control between the residual-accumulation and no-accumulation groups on both posttreatment 18 F-FLT PET (P , 0.0001) and posttreatment 18 F-FDG PET (P 5 0.0081). Conclusion: 18 F-FLT PET during RT and early follow-up facilitates the selection of optimal further therapy and the prediction of outcomes.

show abstract

Current awareness: Pharmacoepidemiology and drug safety

2010

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 23 sections: 1 Reviews; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Teratogens/fetal exposure; 20 Antidiabetic Agents; 21 Contrast Agents; 22 Bone Conservation Agents; 23 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.

show abstract

Safety and efficacy of S-1 chemotherapy in recurrent/metastatic head and neck cancer

Cited by 8 publications

References 28 publications

Prognostic Biomarkers of Salvage Chemotherapy Following Nivolumab Treatment for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma

Prognostic Biomarkers of Salvage Chemotherapy Following Nivolumab Treatment for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma

Usefulness of 3′-Deoxy-3′-¹⁸F-Fluorothymidine PET for Predicting Early Response to Chemoradiotherapy in Head and Neck Cancer

Current awareness: Pharmacoepidemiology and drug safety

Contact Info

Product

Resources

About

Safety and efficacy of S-1 chemotherapy in recurrent/metastatic head and neck cancer

Cited by 8 publications

References 28 publications

Prognostic Biomarkers of Salvage Chemotherapy Following Nivolumab Treatment for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma

Prognostic Biomarkers of Salvage Chemotherapy Following Nivolumab Treatment for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma

Usefulness of 3′-Deoxy-3′-18F-Fluorothymidine PET for Predicting Early Response to Chemoradiotherapy in Head and Neck Cancer

Current awareness: Pharmacoepidemiology and drug safety

Contact Info

Product

Resources

About

Usefulness of 3′-Deoxy-3′-¹⁸F-Fluorothymidine PET for Predicting Early Response to Chemoradiotherapy in Head and Neck Cancer